Colin Kerr
Published: Wednesday, September 2, 2020

VSY Biotechnology has announced the launch of Enova, a 100% glistening-free IOL. The company says Enova is the first 100% glistening-free hydrophobic acrylic IOL that does not require pre-hydration or storage in saline solution.
VSY say the unique composition of Enova material allows uniform hydration of specific sites to have controlled water uptake and resistance to glistening formation. Glistening study was performed at the Intermountain Ocular Research Center (Mamalis/Werner Laboratory), John A. Moran Eye Center, University of Utah and the unique composition of Enova hydrophobic acrylic IOL shows no glistening compared with other IOLs.
“Enova is the first 100% glistening-free hydrophobic acrylic IOL that requires neither pre-hydration nor storage in saline. Enova is packaged dry and has excellent optical and mechanical properties,” said a company spokesman. “Glass transition temperature of a polymer is the temperature where the polymer changes from a rigid material to a soft material. Having a Tg -2°C, Enova IOL has gentle and controlled unfolding process below standard operating room temperatures. Thus, no warming or special conditioning is required. Low glass transition temperature (Tg -2°C) combined with its optimised modulus of elasticity, provides a high level of flexibility and controlled unfolding,” said the spokesman.
www.vsybiotechnology.com
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
Read more...
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Read more...
ESCRS Today 2025: All Eyes on Innovation
Watching out for obstacles and opportunities
Read more...
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Read more...
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Read more...
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Read more...
Supplement: ESCRS Clinical Trends Series: Presbyopia
Read more...
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Read more...
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Read more...
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.
Read more...